ADELPHIA, N.J., Jan. 24 /PRNewswire/ -- Lifeblood Medical, Inc. today officially released its first major study comparing Lifor(R) with the industry's current gold standard for preservation of heart for transplantation. Entitled Room Temperature Ten Hour Heart Preservation Study with Lifor(R), recirculated Lifor(R) successfully preserved guinea pig isolated hearts perfused at low flow with no added oxygen at room temperature for ten hours.
"We are extremely pleased with the outcome of our first major study comparing Lifor(R) to the current industry standard," stated Joseph Fischer, President and Chief Executive Officer of Lifeblood Medical, Inc. "I would like to commend Dr. David R. Harder, PhD and Dr. David F. Stowe, MD, PhD, both of the Medical College of Wisconsin, for their efforts in producing this study. We have successfully proved that Lifor(R) is an effective and convenient preservation medium for hearts during a long transport that would not require severe cooling and refrigeration and supplemental oxygen to restore viability during implantation. Based on such positive results in preserving the heart at room temperature, we will be changing our strategy for organ and tissue preservation. Our first submission for FDA approval will be Lifor(R) for heart preservation and transportation. We believe we can give patients on the waiting list the opportunity to regain their quality of life by increasing the number of hearts available for transplantation through donor organ preservation and transportation at extended hours."
The manuscript is available at
About Lifeblood Medical, Inc.
Lifeblood Medical, Inc., headquartered in Adelphia N.J., is a cell culture/biotech company whose goal is to enhance and extend the quality of life in the field of organ, cell and tissue preservation through the utilization of our proprietary solutions and by providing key reagents to the research community.
We distribute high quality serum and reagents to the research community at competitive prices. Our products include Serum, Serum Enhancers, Antibiotics and Specialty Media.
Our proprietary solution is considered platform enabling technology, with the potential to address a multitude of applications through all segments of the tissue, cell and organ transplant markets by way of its unique serum free, animal protein free and oxygen carrying properties. For the cell and tissue preservation market we offer LiforCell(R). For whole organ preservation, transportation and transplantation we offer LIFOR(R). LIFOR(R) is currently undergoing clinical trials for the support of heart and kidney harvesting, transporting and reimplantation. FDA submission is anticipated later this year. Additional information is available online at http://www.lifebloodmedical.com.
CONTACT: Joseph Fischer, +1-732-431-5833
Lifeblood Medical, Inc.